Kilambi News
Wednesday, November 18, 2026

GeneDx names Everett Cunningham chief executive as Stueland steps down

Life Sciences Wednesday, November 18, 2026 - Updated Nov 18, 2026 09:12

GeneDx chief executive Katherine Stueland will step down and resign from the board when Everett Cunningham, most recently chief executive of Quanterix, starts in the role, expected on or before December 15, the genetic testing company said in an SEC filing.

Why it matters: The change puts a diagnostics commercial leader in charge of GeneDx, with Cunningham having previously led commercial operations at Illumina and Exact Sciences and the United States and Canada region of GE Healthcare.

Data as of GeneDx Holdings Corp. Form 8-K filed November 18, 2026 (accession 0001104659-26-129358), read in full from SEC EDGAR in this run; all appointment, timing and compensation facts are the filing's own. Developing item.

GeneDx Holdings Corp. and Katherine Stueland agreed on November 15 that she will step down as chief executive and resign from the board effective on the first day of employment of Everett Cunningham, expected on or before December 15, 2026, the company said in a Form 8-K filed on Wednesday. The filing said her departure is not related to any disagreement over the company’s operations, policies or practices, and that she will remain as Executive Advisor, reporting to the board, through January 31, 2027.

The board appointed Cunningham as chief executive and as a Class II director effective on the same transition date. He served as president and chief executive of Quanterix Corporation from January 2026 to November 2026, and before that as chief commercial officer of Illumina from June 2024 to January 2026 and of Exact Sciences from 2021 to 2024, after leading GE Healthcare’s United States and Canada region. The filing puts his initial annual base salary at 750,000 dollars, with a target annual cash bonus equal to 100 percent of base salary.

Sources

  1. GeneDx Holdings Corp. Form 8-K, filed November 18, 2026 (accession 0001104659-26-129358) - US Securities and Exchange Commission, EDGAR - 2026-11-18